KINGDOM THERAPEUTICS LIMITED

Kingdom Therapeutics Limited is a clinical‑stage biotechnology company dedicated to pioneering treatments for autism spectrum disorder (ASD) and other neurodevelopmental conditions. By exploring the gut‑brain‑endocannabinoid axis, the firm seeks to understand how these systems interact and to translate that knowledge into novel therapeutics. Their flagship candidate, KT‑20610, is being investigated for its potential to alleviate both behavioural and gastrointestinal symptoms associated with profound autism.

The company brings together leading experts from pharmaceutical development, cannabinoid science, healthcare and intellectual‑property law, working hand‑in‑hand with representatives from the patient community to ensure that research remains focused on real‑world needs. Kingdom Therapeutics collaborates with top contract research organisations, such as Novotech, to drive its groundbreaking clinical trials forward. Recent milestones include a positive pre‑IND outcome and strategic advisory input positioning the UK as a future hub for cannabinoid R&D.

With a clear scientific vision and a multidisciplinary team, Kingdom Therapeutics is building hope through science, aiming to deliver safe, effective treatments that improve quality of life for individuals with ASD and their families.